These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38536949)

  • 1. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy.
    Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
    Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
    Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
    Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
    Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
    Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
    J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer.
    Zhang T; Bai L; You R; Yang M; Chen Q; Cheng Y; Qian Z; Wang Y; Liu Y
    J Mater Chem B; 2024 Jun; 12(22):5465-5478. PubMed ID: 38742364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Three-in-one": A Photoactivable Nanoplatform Evokes Anti-Immune Response by Inhibiting BRD4-cMYC-PDL1 Axis to Intensify Photo-Immunotherapy.
    Mohanty A; Lee M; Mohapatra A; Lee H; Vasukutty A; Baek S; Lee JY; Park IK
    Adv Healthc Mater; 2024 Jul; 13(17):e2304093. PubMed ID: 38409920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
    Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
    EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer.
    Qian X; Yang H; Ye Z; Gao B; Qian Z; Ding Y; Mao Z; Du Y; Wang W
    ACS Nano; 2024 Jun; 18(24):15864-15877. PubMed ID: 38829727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
    Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
    Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-targeting MOFs nanoplatform for treating metastatic triple-negative breast cancer through tumor microenvironment remodeling and chemotherapy potentiation.
    Wu H; Jin M; Liu Y; Wang S; Liu C; Quan X; Jin M; Gao Z; Jin Y
    Int J Pharm; 2024 Oct; 664():124625. PubMed ID: 39182743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
    Wu Y; Chen R; Ni S; Hu K
    J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-cloaked alginate-poly (β-amino ester) a novel platform bioinspired polyelectrolyte nanoparticle for targeted delivery of carboplatin in breast cancer: An in vitro/in vivo study.
    Akbari A; Varshosaz J; Minaiyan M; Heydari P; Talebi A; Salahi M; Jahanian Najafabadi A
    Int J Pharm; 2024 Nov; 665():124720. PubMed ID: 39284421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhein and hesperidin nanoparticles remodel tumor immune microenvironment by reducing CAFs and CCL2 secreted by CAAs for efficient triple-negative breast cancer therapy.
    Huang J; Zhang H; Ma L; Ma N; Luo N; Jin W; Shi J; Xu S; Xiong Y
    Int Immunopharmacol; 2024 Nov; 141():113001. PubMed ID: 39186835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.